Form 4: Arcadia Biosciences CFO Acquires Shares Through Employee Stock Purchase Plan

Mark Kawakami, CFO of Arcadia Biosciences, reports the acquisition of 700 shares of common stock through the company's Employee Stock Purchase Plan at a price of $2.06 per share.

Summary

• On August 1, 2024, Mark Kawakami, the Chief Financial Officer of Arcadia Biosciences, acquired 700 shares of the company's common stock.
• The shares were purchased at $2.06 per share through the company's 2015 Employee Stock Purchase Plan (ESPP).
• The purchase price was 85% of the closing price of Arcadia Biosciences' common stock on the purchase date, as per the ESPP terms.
• Following the transaction, Kawakami directly owns 1,981 shares of Arcadia Biosciences common stock, including ESPP purchases from February 1, 2022, to August 1, 2024.
• These ESPP transactions are exempt from Rule 16b-3(c).

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction (ESPP purchase) indicating confidence but not a major event.

Positives

• The CFO's participation in the ESPP demonstrates confidence in the company's future.

Industry Context

This is a routine transaction related to employee compensation and is common in publicly traded companies. It reflects an executive's investment in their own company.

Comparison to Industry Standards

• Employee stock purchase plans are a common form of compensation in publicly traded companies.
• The discount of 15% from the closing price is a typical feature of ESPPs.
• Executive participation in ESPPs is generally viewed positively by investors as it aligns management's interests with those of shareholders.

Stakeholder Impact

• The transaction could have a slightly positive impact on shareholder sentiment due to the CFO's increased investment in the company.

Key Dates

Keywords

Arcadia Biosciences, RKDA, CFO, Mark Kawakami, Employee Stock Purchase Plan, ESPP, Share Acquisition, Form 4